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Introduction {#sec1}
============

It is currently unknown why HIV-associated neurocognitive disorders (HAND) persist despite effective viral suppression to undetectable levels in most combination antiretroviral therapy (cART)-treated individuals. Although patients on successful cART show sustained viral suppression, as indicated by routine plasma monitoring and occasional cerebrospinal fluid (CSF) monitoring, "blips" indicative of transient HIV replication are often detected with more frequent testing, as reviewed in [@bib12]. A number of studies link persistent immune activation, neuroinflammation, and CSF viral escape in cART-treated individuals to increased disease progression, as well as an increased risk for HAND ([@bib14], [@bib18], [@bib42]). Interruption of cART has been associated with CSF viral escape and neuronal injury, as well as with worsened neurocognitive performance ([@bib14], [@bib18], [@bib42]). Although fulminant encephalitis is now uncommon in HIV-infected patients, biomarkers of continuing neuroinflammation in the CSF and brain, as well as neuronal injury, are frequently detected in virally suppressed individuals. Still, partial protection against HAND by successful cART does indicate some direct link to HIV replication. Persistent HIV infection and reactivation from central nervous system (CNS) reservoirs, even if intermittent, appears likely in cART-experienced patients ([@bib58]). Brain infection may also be re-seeded through blood or through recently described meningeal lymphatics ([@bib27]). In addition, evidence for the involvement of CD8^+^ T cells, especially through production of interferon (IFN)-γ, in CNS pathogenesis in patients who received cART continues to mount ([@bib53]). Therefore, CSF viral escape and the associated production of viral antigen (Ag), as well as its generation of subsequent adaptive, recall responses by brain-resident CD8^+^ T cells to control viral spread, may induce neuroinflammation that drives bystander CNS injury.

Resolution of adaptive immune responses and generation of immunological memory is an essential process to confer long-term protective immunity, particularly in tissues like the brain. The presence of CD8^+^ T cells in post-mortem brains of HIV-infected patients, as well as in the brains of animal models, is well documented ([@bib16], [@bib19], [@bib20], [@bib22], [@bib26], [@bib35], [@bib53]). Recent studies have demonstrated that following clearance of many acute viral infections, CD8^+^ T lymphocytes generate a population of long-lived, non-recirculating tissue-resident memory T cells (T~RM~) in non-lymphoid tissue, and it is becoming increasingly clear that these T~RM~ play critical roles in controlling re-encountered pathogens and accelerating the process of clearance ([@bib32], [@bib38], [@bib46], [@bib52]). It is well established that during acute viral infection, most pathogens are rapidly cleared by the generation of a large number of short-lived effector T cells (SLEC), which die via apoptosis once cognate Ag is cleared. Simultaneously, the T cell response is also triggered to generate a defined subset identified as memory precursor effector cells (MPEC). These MPEC begin to develop into a T~RM~ phenotype shortly after infection. Recent work by several groups provides evidence that there is a clear distinction between terminal effector and memory cells based on heterogeneity in expression of killer cell lectin-like receptor G1 (KLRG1) ([@bib2], [@bib23], [@bib69]).

We have recently characterized brain-infiltrating T cells that persist within the CNS after acute murine cytomegalovirus (MCMV) infection ([@bib48]). We have also shown that these brain CD8^+^ T cell populations shift from SLEC that clear infection to MPEC that protect against viral reactivation and re-challenge. The shift of prominent SLEC populations to MPEC populations is concomitant with transition from acute through chronic phases of infection. T~RM~ are characterized by their non-recirculating, resident nature in tissues. It has been well reported that T~RM~ often express αEβ7 integrin, and integrin αE, otherwise known as CD103, is used as a marker of particular types of T~RM~. High expression of CD103 and CD69 is a common feature of resident memory cells observed in epithelial tissue, as well as a phenotypic signature of bT~RM~ ([@bib59], [@bib64], [@bib65], [@bib67]). In contrast, effector and memory cells in circulation appear to lack expression of both CD103 and CD69 ([@bib17], [@bib37]). It has also been shown that CD69 expression is required for optimal formation of T~RM~ following herpes simplex virus infection in tissues such as the skin and dorsal root ganglia ([@bib32], [@bib34]). In addition to CD103^+^ and CD69^+^ markers, T~RM~ are often reported to express CD49a. CD49a constitutes the α subunit of α1β1 integrin receptor, also known as very late Ag 1 (VLA-1) ([@bib13]). Experiments using skin, lung, and gut show differential expression of CCR7, as well as CXCR3, which define migration properties of T cells ([@bib43], [@bib55]). Although imperfect, expression of these markers is frequently used to identify T~RM~ populations when stringent migration studies, such as parabiosis, are not feasible, reviewed in [@bib52]. Finally, protection of the CNS from reinfection by lymphocytic choriomeningitis virus (LCMV) was found to depend on these brain-resident memory CD8^+^ T cells (bT~RM~) ([@bib59]).

Given their significance in antiviral defense, surprisingly little is known about this brain-resident memory cell population in the context of HAND. Ag-specific lymphocytes residing within tissues are uniquely poised to respond rapidly to their cognate Ag, and T~RM~ functions extend far beyond cytotoxic T lymphocyte activity. In several infection models, it is clear that recall responses of T~RM~ to small amounts of Ag result in production of IFN-γ ([@bib40], [@bib59]). Furthermore, this IFN-γ production results in IFN-stimulated gene expression in surrounding cells, thereby amplifying the activation of a small number of adaptive immune cells into an organ-wide antiviral response ([@bib1]). Similarly, activation of adaptive immune responses from T~RM~ has been shown to stimulate protective, innate responses in the LCMV model ([@bib52]). From these studies, it is clear that a small number of T~RM~ accelerate pathogen control in the event of reinfection or reactivation of latent infection by instructing tissue-resident innate immune cells, such as microglia. Yet there have been no definitive experiments to evaluate neurotoxic consequences of anti-HIV recall immune response by bT~RM~ in driving tissue-wide activation of brain-resident microglial cells, its associated neurotoxicity, and development of subsequent neurocognitive impairment. Here, we demonstrate that HIV-specific T~RM~ are elicited within brain using a heterologous prime-CNS boost strategy. We show that Ag-specific CD8^+^ bT~RM~ are established, which recognize an immunodominant viral epitope. Subsequent recall responses to specific epitope peptides resulted in striking upregulation of major histocompatibility complex (MHC) class II (MHC-II) and programmed death-ligand 1 (PD-L1) on microglial cells, indicative of neuroinflammation. Taken together, data presented here show that recall responses from bT~RM~ can induce reactive gliosis.

Results {#sec2}
=======

Ag-Specific CD8^+^ T Cells Infiltrate and Are Retained within the Brain following Priming with rAd5-p24 and CNS Boosting Using Pr55^Gag/Env^ HIV-VLPs {#sec2.1}
-----------------------------------------------------------------------------------------------------------------------------------------------------

To investigate whether recall responses from bT~RM~ can induce reactive gliosis, we first established a population of HIV-specific T cells within the murine brain using a heterologous prime-CNS boost strategy. To accomplish this, BALB/c mice were primed via tail vein injection with recombinant adenovirus vectors expressing the HIV-1 p24 capsid protein (rAd5-p24). This priming step was followed by a CNS-boost using Pr55^Gag/Env^ virus-like particles (HIV-VLPs) injected directly into the striatum ([Figure 1](#fig1){ref-type="fig"}A). Using immunohistochemical (IHC) staining, we first confirmed that the adenovirus construct delivered bona fide HIV-p24 protein by staining murine liver sections 7 days post-priming ([Figure S1](#mmc1){ref-type="supplementary-material"} A). We then detected increased lymphocyte trafficking into the brains of rAd5-p24-primed animals, which received an HIV-VLP CNS boost when compared with control animals that were primed, but did not receive HIV-1 Ag in the brain ([Figures 1](#fig1){ref-type="fig"}B and 1C). We observed that CD8^+^ T cells infiltrated the brain and were present at 7 days post HIV-VLP injection, and further increased at 30 days post prime-CNS boost ([Figure 1](#fig1){ref-type="fig"}C). In addition, we used tetramer staining to confirm that AI9-specific, but not LCMV epitope-specific, CD8^+^ T cells were present at 7 days and continued to persist until at least 30 days post prime-CNS boost ([Figures 1](#fig1){ref-type="fig"}D and 1E). We also examined the recruitment of CD4^+^ T cells and observed an influx into the brain at 7 days following prime-CNS boost (38.3%). The frequency of CD4^+^ T cells increased by 30 days (42.2%), similar to that observed for CD8^+^ T cells. However, by 60 days the frequencies of both CD8^+^ and CD4^+^ T cells decreased (20.8% and 32.9%, respectively). In addition, as a result of AI9 *in vivo* restimulation, the frequency of CD8^+^ T cells was elevated by 2 days post-peptide injection, whereas CD4^+^ T cell frequency was not ([Figure S2](#mmc1){ref-type="supplementary-material"}A).Figure 1Lymphocyte Infiltration into the Brain and Long-Term Presence of Ag-Specific CD8^+^ T Cells following Heterologous Prime-CNS Boost(A) Schematic of the experimental model illustrates intravenous delivery of recombinant adenovirus vectors expressing HIV-1 p24 capsid protein (rAD5-p24), followed by a CNS-boost consisting of intracranial injection of HIV-VLPs into the striatum. BMNC were collected at 7 and 30 days post prime-boost.(B) Flow cytometric analysis demonstrating lymphocyte infiltration and CD8^+^ T cell retention within the brain following heterologous CNS boost.(C) Absolute numbers of CD8^+^ T cells were determined within brains of animals at the indicated time points.(D) Dot plot comparing the frequencies of AI9 tetramer-specific CD8^+^ T cells in brain tissue isolated from rAd5-p24/Sal (saline) and rAd5-p24/HIV-VLP groups.(E) Bar graph presents absolute numbers of T cells between groups. Pooled data are presented as mean ± SD of two independent experiments using four to six animals per group per time point. \*\*p \< 0.01

Memory CD8^+^ T Cells Are Present within the Brain following Prime-CNS Boost Strategies {#sec2.2}
---------------------------------------------------------------------------------------

To characterize HIV-specific CD8^+^ T cells within the brain, we analyzed Ag-specific cells for phenotypic markers at both 7 and 30 days post prime-CNS boost ([Figure 2](#fig2){ref-type="fig"}A). We first determined the pattern of CD127 and KLRG1 expression on these Ag-specific cells. We observed expression of CD127 on some Ag-specific CD8^+^ T cells during the acute phase of infection, whereas a larger fraction of AI9 tetramer^+^ CD8^+^ T cells displayed high CD127 expression at 30 days post prime-CNS boost ([Figure 2](#fig2){ref-type="fig"}B). In sharp contrast, KLRG1 expression was found to be 37.8% ± 3.4% among Ag-specific cells during onset of infection, whereas it decreased to 19.8% ± 2.7% at 30 days ([Figures 2](#fig2){ref-type="fig"}B and 2C). To gain insight into the diversity of T~RM~ phenotypes, we next examined the relative expression of various residency markers such as CD103, CD69, and CD49a. An increased expression of CD69 at 7 days suggested that these Ag-specific CD8^+^ T cells progress to an activated state. Expression of CD49a was also observed during establishment of infection. Interestingly, expression of both CD69 and CD49a remained elevated even at 30 days. Their increased co-expression was also observed during the chronic phase (81.1% ± 3.8%; [Figures 2](#fig2){ref-type="fig"}B and 2C). Moreover, high co-expression of CD69 and CD103 (74% ± 3.5%), as well as CD127 and CD103 (75% ± 1.3%), was observed. In addition, an increased proportion of Ag-specific CD8^+^ T cells was found to co-express CD49a and CD103 (67.9% ± 0.3%), as well as CD49a and CD127 (84.2% ± 1.1%) ([Figures 2](#fig2){ref-type="fig"}B and 2C). Evaluation of various memory marker-expressing cells revealed greater numbers of T~RM~ at 30 days than at 7 days following prime-CNS boost ([Figure 2](#fig2){ref-type="fig"}D). Finally, we also observed that these Ag-specific CD8^+^CD103^+^ T cells also expressed programmed cell death (PD)-1 (72.5% ± 0.8%) ([Figures 2](#fig2){ref-type="fig"}E and 2F). Furthermore, evaluation of additional transcription factors associated with tissue residency revealed elevated levels of B lymphocyte-induced maturation protein (Blimp)-1 and eomesodermin (Eomes), whereas reduced levels of T-box expressed in T cells (T-bet) were seen at 30 days post prime-CNS boost ([Figures 2](#fig2){ref-type="fig"}G and 2H).Figure 2Phenotypic Characterization of Ag-Specific T~RM~ within the Brain(A and B) CNS-derived lymphocytes were gated for AI9-specific CD8^+^ T cells and analyzed for the indicated memory cell markers (CD127, CD103, CD69, CD49a), as well as the short-lived effector marker KLRG1.(C and D) Bar graphs present pooled frequencies and number of Ag-specific cells that expressed the indicated phenotypic markers.(E) Additional contour plots show PD-1 expression on these Ag-specific CD103^+^ CD8^+^ T cells at 7 and 30 days post prime-boost.(F) Pooled data show frequency of PD-1 expression on Ag-specific CD103^+^CD8^+^ T cells at the indicated time points. \*\*p \< 0.01.(G) Representative plots show expression of transcription factors Blimp-1, Eomes, and T-bet at the indicated time point.(H) Pooled data present percentage of Blimp-1, Eomes, and T-bet expression. Graph presents data combined from two separate experiments using four to six animals per group per time point.

Effector Responses of bT~RM~ {#sec2.3}
----------------------------

To investigate the ability of bT~RM~ to respond to restimulation, we evaluated the production of IFN-γ and interleukin-2 (IL-2), as well as granzyme B. Analysis was performed using intracellular staining and flow cytometry following *ex vivo* stimulation with AI9 peptide, which is an immunodominant, H-2K^d^ MHC-I-restricted T cell epitope from the p24 (65-73) capsid. Brain-derived CD8^+^CD103^+^ T~RM~ produced IFN-γ following peptide stimulation. Higher frequencies (55.8% ± 7.3%) were produced following *ex vivo* peptide stimulation when compared with unstimulated control (3.0% ± 0.43%, p \< 0.05) ([Figures 3](#fig3){ref-type="fig"}A and 3B). We also analyzed dual cytokine production by assessing IFN-γ and IL-2 co-expression. A substantial percentage of dual IFN-γ- and IL-2-producing CD8^+^CD103^+^ T cells (30.4% ± 4.0%) was detected following peptide restimulation ([Figures 3](#fig3){ref-type="fig"}A and 3B). Increased production of tumor necrosis factor (TNF)-α was also noted in response to *ex vivo* AI9 restimulation ([Figures 3](#fig3){ref-type="fig"}C and 3D). In addition, granzyme B-expressing cells were also detected in a larger proportion (39.2% ± 3.6%) when compared with unstimulated control (8.4% ± 1.3%) ([Figures 3](#fig3){ref-type="fig"}E and 3F). Finally, we analyzed the proliferation potential of these CD103^+^CD8^+^ T cells following Ag stimulation and found that Ki67 was expressed in a significant fraction, whereas unstimulated cells displayed lower levels (35.3% ± 6.1% and 10.2% ± 1.4%, respectively) ([Figures 3](#fig3){ref-type="fig"}G and 3H).Figure 3Ag-Specific CD103^+^CD8^+^ T Cells Display Recall ResponsesBMNC obtained from animals at 30 days post prime-CNS boost were either restimulated *ex vivo* with AI9 peptide or left unstimulated, and intracellular staining was performed. Gated CD103^+^CD8^+^ T cells were assessed for cytokine production in response to peptide stimulation.(A) Representative contour plots present expression of IFN-γ and IL-2 by CD103^+^CD8^+^ T cells.(B) Bar graph of pooled data shows frequencies of IFN-γ production by CD103^+^CD8^+^ T cells, as well as simultaneous detection of IFN-γ and IL-2 double-producer cells.(C) Contour plots show TNF-α production by CD103^+^CD8^+^ T cells.(D) Pooled data show the frequency of TNF-α production.(E) Representative contour plots of granzyme B show *ex vivo* production of this cytotoxic mediator in response to peptide stimulation.(F) Data presented show percentage of granzyme B-producing CD103^+^CD8^+^ T cells.(G) Contour plots following Ki67 staining show proliferation frequencies of CD103^+^CD8^+^ T cells, either with or without peptide stimulation.(H) Pooled data present percentage proliferation of bT~RM~.\*\*p \< 0.01 and \*\*\*p \< 0.001

Glial Cell Activation following Peptide Restimulation {#sec2.4}
-----------------------------------------------------

Having observed that *ex vivo* stimulation resulted in cytokine production, we went on to determine the capacity of these viral-peptide-induced recall responses to activate glia. In these experiments, brain-derived mononuclear cells (BMNC) obtained from prime-CNS boost mice at 30 days were co-cultured with primary murine glial cells (40% microglia, 60% astrocytes) and stimulated with either the AI9 peptide or the non-specific M54 peptide epitope from MCMV. Increased transcription of proinflammatory mediators (i.e., IFN-γ, CXCL9, CXCL10, nitric oxide synthase \[iNOS\], and PD-1) was observed in the co-cultures after 24 h of stimulation with specific (AI9), but not non-specific (M54), T cell epitope peptides ([Figure 4](#fig4){ref-type="fig"}A). Also, elevated levels of MHC-II, PD-L1, and Iba (ionized calcium-binding adaptor molecule)-1 mRNA indicated glial cell activation in response to AI9, but not M54, peptide ([Figure 4](#fig4){ref-type="fig"}A). To specifically evaluate the role of CD8^+^ T cells in modulating glial activation, we used positive selection to deplete this T cell population from the BMNC isolated from prime-CNS boost animals at 30 days. Depletion of CD8^+^ T cells was confirmed using flow cytometry ([Figure S2](#mmc1){ref-type="supplementary-material"}B). The sorted BMNC (i.e., with and without CD8^+^ T cells) were then cultured with mixed glial cells, and transcription of the same proinflammatory mediators was assessed after 48 h. Depletion of CD8^+^ T cells was found to reduce transcription of IFN-γ as well as the IFN-γ-induced chemokines CXCL9 and CXCL10. Reductions in transcription of MHC-II, PD-L1, Iba-1, iNOS, and PD-1 were also observed in the absence of CD8^+^ T cells ([Figure 4](#fig4){ref-type="fig"}B). Also, to determine the individual contribution of each glial cell type, we assessed cytokine and chemokine production at the protein level from co-cultures of AI9-stimulated BMNC reconstituted with either primary microglial cells or primary astrocytes. ELISA results indicated that BMNC produced IFN-γ, in response to AI9 restimulation, either when cultured alone or when reconstituted with either microglia or astrocytes ([Figure 4](#fig4){ref-type="fig"}C). Elevated levels of CXCL9 ([Figure 4](#fig4){ref-type="fig"}D) and CXCL10 ([Figure 4](#fig4){ref-type="fig"}E) were found in the BMNC-glial cell co-cultures, but not from AI9-stimulated BMNC alone. Co-cultures of unstimulated BMNC (i.e., no AI9 treatment) with either microglia or astrocytes produced negligible levels of IFN-γ, CXCL9, or CXCL10 ([Figure 4](#fig4){ref-type="fig"}C--4E). Interestingly, treatment of the co-cultures with an anti-IFN-γ neutralizing antibody significantly reduced subsequent glial cell expression of CXCL9 and CXCL10 when compared with IgG isotype antibody ([Figures 4](#fig4){ref-type="fig"}F and 4G).Figure 4Specific *Ex Vivo* Peptide Restimulation of T Cells Activates Primary Glial Cells(A) BMNC isolated from brains of 30 days post prime-boost animals were co-cultured with primary murine glial cells (40% microglia; 60% astrocytes). Cells were either treated with HIV-specific AI9 or MCMV M54 T cell epitope peptides or left untreated for 24 h. Real-time PCR data show mRNA expression levels of IFN-γ, MHC-II, PD-L1, PD-1, Iba-1, CXCL9, CXCL10, and nitric oxide synthase (iNOS) under the indicated treatment.(B--G) (B) Cultures with or without the CD8 T cell population were either stimulated with AI9 peptide or left unstimulated for 1 h before being co-cultured with mixed glial cells (40% microglia; 60% astrocytes) for 24 h. qPCR data presenting transcript levels of IFN-γ, MHC-II, PD-L1, PD-1, Iba-1, CXCL9, CXCL10, and iNOS under the indicated treatment. Data shown are representative of two separate experiments. Supernatants from AI9-stimulated or unstimulated BMNC co-cultured either with microglial cells or astrocytes were collected at 48 h and ELISA was performed for IFN- γ (C), CXCL9 (D), and CXCL10 (E). Blocking of IFN-γ using a neutralizing anti-IFN-γ antibody inhibited CXCL9 (F) and CXCL10 (G) expression. The results shown are from pooled data of two independent experiments. \*\*\*p \< 0.001.

*In vivo* Recall Responses Stimulate Rapid Proliferation of HIV-Specific bT~RM~ within the Brain {#sec2.5}
------------------------------------------------------------------------------------------------

It is well-established that T~RM~ respond rapidly to an Ag re-challenge ([@bib52]). Our *ex vivo* studies demonstrated that IFN-γ and IFN-γ-inducible chemokines, as well as microglial activation makers, were produced following peptide-specific stimulation. To study recall responses *in vivo*, we intracranially administered either the Ag-specific peptide AI9 or an irrelevant peptide or saline to animals at 30 days post prime-CNS boost ([Figure 5](#fig5){ref-type="fig"}A). We first found that recall activation following injection of HIV-specific peptide resulted in an increased number of AI9 tetramer^+^ CD8^+^ T cells within the brain ([Figure 5](#fig5){ref-type="fig"}B). This effect was specific to AI9 peptide and was not observed with irrelevant peptide (M54) or saline (Sal) ([Figures 5](#fig5){ref-type="fig"}B and 5C). We went on to determine that brain-resident CD103^+^CD8^+^ T cells expanded following *in vivo* restimulation. Ki67 staining demonstrated this increased bT~RM~ proliferation in response to AI9 restimulation relative to the control group ([Figures 5](#fig5){ref-type="fig"}D and 5E).Figure 5*In Vivo* Recall Responses Stimulate Proliferation of Brain-Resident HIV-Specific CD8^+^ T CellsBMNC obtained from prime-CNS boost animals were collected and evaluated using flow cytometry at the indicated time points following *in vivo* peptide restimulation.(A) Schematic representation of experimental approach to evaluate *in vivo* recall responses. The AI9 peptide, an irrelevant T cell epitope peptide (M54), or saline were injected into the brain and tissues were collected at 2 and 5 days post-restimulation.(B) Dot plots show tetramer-specific CD8^+^ T cells in the brain at 2 days post-peptide restimulation.(C) Bar graph presents numbers of HIV-specific CD8^+^ T cells following the indicated restimulation.(D) Contour plots present Ki67 expression on CD103^+^CD8^+^ T cells at 2 days post-restimulation with cognate peptide.(E) Bar graph represents the pooled frequencies of Ki67-expressing CD103^+^CD8^+^ T cells. Data are presented as mean ± SD of two independent experiments using four animals in control or irrelevant peptide groups and six animals following AI9 restimulation. \*\*p \< 0.01

Recall Responses Induce Glial Cell Activation {#sec2.6}
---------------------------------------------

Having observed that T~RM~ isolated from the brain produce abundant proinflammatory cytokines following AI9 peptide stimulation *ex vivo*, we next investigated the *in vivo* induction of reactive gliosis. We first assessed the kinetics of MHC-II and PD-L1, which are markers of activation, expression on microglial cells at both 7 and 30 days post prime-CNS boost. Unstimulated microglia, identified as the CD45^int^CD11b^+^ population using flow cytometry ([Figure S3](#mmc1){ref-type="supplementary-material"}A), have been reported to express minimal levels of MHC-II and PD-L1 ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C), whereas a reactive microglial cell phenotype was observed following our prime-CNS boost regimen. Increased expression of MHC-II on microglial cells was first observed during the acute phase (39.5% ± 2.4%) and remained elevated at 30 days post prime-CNS boost (10.5% ± 2.5%), when compared with the control group 5.3% ± 0.4% and 3.2% ± 0.4% at 7 and 30 days, respectively ([Figures 6](#fig6){ref-type="fig"}A and 6B). Similarly, expression of PD-L1 was also upregulated at 7 days (30.3% ± 2.6%) and it continued to be expressed at the 30-day time point (17.9% ± 2.2%) ([Figures 6](#fig6){ref-type="fig"}C and 6D). PD-L1 expression on microglia was minimal in the control animals (2.8% ± 0.3% and 3.7% ± 0.7% at 7 and 30 days, respectively).Figure 6*In Vivo* Recall Responses by bT~RM~ Induce Microglial Cell ActivationFlow cytometry and IHC staining were performed on brain tissue obtained from mice following prime-CNS boost.(A) Contour plots present expression of MHC-II on CD45^int^/CD11b^+^ microglia at 7 and 30 days post prime-CNS boost.(B) Pooled data show the frequencies of MHC-II expression at the indicated time points both pre- and post-recall restimulation via intracranial injection of AI9 peptide.(C) Contour plots present expression of PD-L1 on stimulated CD45^int^/CD11b^+^ microglial cells at 7 and 30 days post prime-boost.(D) Bar graph presented shows frequencies of PD-L1 expression at the indicated time points both pre- and post-restimulation.(E) Representative contour plots show percentage of microglia expressing MHC-II at 2 and 5 days post *in vivo* AI9 restimulation.(F) Representative contour plots show the percentage of microglial cells expressing PD-L1 at 2 and 5 days post *in vivo* restimulation. Data presented are mean ± SD of two independent experiments using six animals in control and irrelevant peptide groups at all time points and six to eight animals in the AI9 restimulation group at 7- and 30-day time points, respectively.\*\*\*p \< 0.001.

To investigate the effect of recall responses on brain-resident glia, we examined microglial cell activation at 2 and 5 days following restimulation via intracranial injection of AI9 peptide (i.e., at 30 days post prime-CNS boost). We again analyzed MHC-II and PD-L1 expression as microglial activation markers. Interestingly, specific Ag restimulation rapidly induced upregulation of MHC-II expression on microglia cells (74.6% ± 2.9% at 2 days and 49.2% ± 1.6% at 5 days post-restimulation) ([Figures 6](#fig6){ref-type="fig"}E and 6B). Similarly, microglia also displayed an increase in PD-L1 (72.4% ± 3.3% at 2 days) that remained elevated (65.1% ± 2.6%) at 5 days following AI9 peptide. Importantly, glial cell activation was not observed in response to MCMV M54 peptide restimulation or saline ([Figures 6](#fig6){ref-type="fig"}F and 6D). In addition, i*n vivo* recall immune responses from bT~RM~ may also augment cytotoxic activity within the brain ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B).

Reactive Glial Cell Phenotypes in Response to *In Vivo* AI9 Restimulation {#sec2.7}
-------------------------------------------------------------------------

We performed IHC on sections of brain obtained from primed-CNS boost mice following 2-day recall stimulation (+AI9), co-staining for MHC-II and Iba-1. Microglial cells within these sections displayed a reactive phenotype, as observed by elevated expression of MHC-II and Iba-1 ([Figure 7](#fig7){ref-type="fig"}A). Double immunostaining with anti-TMEM119 (a microglial cell-specific marker) and Iba-1 revealed co-localization following *in vivo* AI9 restimulation ([Figure 7](#fig7){ref-type="fig"}A). Expression of CXCL10 was also seen in several locations within the restimulated brain: it was evident in the hippocampus, ventricles, and parenchyma ([Figure 7](#fig7){ref-type="fig"}B). Most interestingly, dual staining of CXCL10 with Iba-1, as well as the astrocyte marker glial fibrillary acidic protein (GFAP), demonstrated greater co-localization of CXCL10 in the GFAP^+^ population than in the Iba-1^+^ cells ([Figure 7](#fig7){ref-type="fig"}C). This finding demonstrated that specific recall responses of bT~RM~ also stimulated astrocytes.Figure 7Recall Responses from bTRM Cells Induce Reactive Glial Cell Phenotypes(A) Dual IHC staining of brain sections obtained from animals at 2 days post-AI9 restimulation for MHC-II and Iba-1, as well as Iba-1 and TMEM119.(B) IHC staining displaying expression of CXCL10 in the hippocampus (H), parenchyma (P), and ventricle (V) of AI9-restimulated animals.(C) Images of CXCL10 co-staining with Iba-1, as well as co-expression of CXCL10 and GFAP.

Discussion {#sec3}
==========

During early HIV-1 infection, CD8^+^ T cell responses play essential roles in viral clearance. As infection proceeds, T~RM~ develop and persist long term in a number of tissues, such as the gastrointestinal tract and female reproductive tract ([@bib25], [@bib62]). These T~RM~ provide robust and immediate effector immune responses to localized reinfection or reactivation of Ag production. The brain is recognized as an important reservoir for latent HIV-1, as well as viral reactivation ([@bib21]). Like other tissues, T~RM~ formation within brain has been demonstrated in several viral infection models ([@bib17], [@bib49], [@bib64]). It is particularly important to understand recall responses of bT~RM~ because although they appear to be critical in controlling virus, long-term persistent neuroinflammation may lead to deleterious neurocognitive consequences.

Prime-boost regimens have emerged as powerful tools to enhance tissue-infiltrating Ag-specific T cells ([@bib61], [@bib62], [@bib70]). Likewise, the heterologous prime-CNS boost approach used in this study was able to induce brain infiltration of Ag-specific CD8^+^ T cells. A fraction of these bT~RM~ can be isolated from brain tissue using *ex vivo* dissociation methods. It has been reported that lymphocyte extraction methods fail to efficiently capture all the cells from non-lymphoid tissue and that the efficiency of T~RM~ isolation varies greatly between histologically distinct locations ([@bib60]). However, the heterologous prime-CNS boost approach used here does provide for the long-term retention of Ag-specific memory cells within the CNS. This observation is in agreement with studies by others wherein Ag-specific CD8^+^ T cells are preferentially retained in non-lymphoid tissue, even after resolution of infection ([@bib24], [@bib61], [@bib62]).

Results presented here demonstrate that long-term retention of HIV-specific CD8^+^ T cells within brain is coupled with the presence of markers of T~RM~. High frequencies of CD8^+^CD103^+^CD69^+^CD49a^+^ were apparent on T cells during the chronic phase following prime-CNS boost. Phenotyping of Ag-specific CD8^+^ T cells infiltrating the brain revealed distinct populations of SLEC and MPEC from acute into chronic phases. The KLRG1^+^ population (i.e., SLEC) dominates at 7 days post prime-CNS boost. In contrast, later time points correlate with development of KLRG1^−^ CD127^+^ cells (MPEC). The Ag-specific CD8^+^ T cells expressed surface CD103, an integrin binding to E-cadherin, and co-expressed CD69 at 30 days. Consistent with other studies, where T~RMs~ in barrier tissues express CD49a and display cytotoxic potential ([@bib13]), we found that CD49a was expressed along with other markers of tissue residency; specific peptide stimulation induced granzyme B production ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B).

In addition to CD103, CD8^+^ T~RM~ in non-lymphoid tissue, including human brain, are defined by the CD69 marker ([@bib24], [@bib56]). CD69 is an activation marker expressed early that aids in T~RM~ retention by downregulating cell surface expression of S1P1, thereby blocking T cell movement out of tissues ([@bib33], [@bib46]). Our findings are similar to those of other studies, where HIV-specific CD8^+^ T~RM~ were established in murine vaginal mucosa using combined intranasal and intravaginal immunization with recombinant influenza vector ([@bib62]). Generation of long-lived Ag-specific T cell memory has also been demonstrated in mucosal tissue following micro-needle array delivery of adenovirus type 5 vectors encoding HIV-1 Gag ([@bib70]). Here, we showed that in our prime-CNS boost model, HIV-1-specific CD8^+^ T cells displayed phenotypic signatures indicative of T~RM~. Recent studies identify the transcription factors Blimp-1 and homolog of Blimp-1 in T cells (Hobit) in promoting T~RM~ cell development. Blimp and Hobit cooperate to repress genes such as Klf2, S1pr1, and CCR7 (required for tissue egress) and thus contribute to the establishment of tissue residency ([@bib3]). Similar to these findings, our study demonstrated expression of Blimp-1, along with low levels of T-bet, indicative of long-lived memory cells. Differential expression of these transcription factors in different microenvironments corresponding to varying degrees of inflammation is likely.

T~RM~ survey for their cognate Ag and initiate tissue-wide inflammation to enhance pathogen clearance. T~RM~ that produce abundant IFN-γ and TNF-α, as well as mediators of cytotoxicity, have been identified in a number of infection models ([@bib44], [@bib48], [@bib59]). HIV-1-specific CD8^+^ T~RM~ have been shown to participate in local antiviral immunity ([@bib25]). IFN-γ, together with other proinflammatory cytokines, has been shown to induce chemokines and establish chronic immune activation during HIV-1 infection ([@bib50]). In skin, it has been demonstrated that CD49a^+^ T~RM~ produce IFN-γ and rapidly gain cytotoxic capacity in response to IL-15 ([@bib13]). Here, we also demonstrated elevated levels of cytokine production and cytolytic potential of T~RM~ in terms of IFN-γ, IL-2, TNF-α, and granzyme B production. IFN-γ promotes long-term microglial cell activation and TNF- α production ([@bib45]). The synergistic action of IFN-γ and TNF- α within the brain has been reported to induce nitric oxide-induced neurodegeneration ([@bib4]). *In vivo* recall immune responses from bT~RM~ may also augment cytotoxic activity within the brain. These findings indicate that potent anti-HIV responses develop upon restimulation with specific T cell epitopes. Our findings are similar to those of other studies wherein robust polyfunctional Gag-specific responses of T~RM~ contribute to HIV-1-specific immunity ([@bib61], [@bib62], [@bib70]).

Although the presence of Ag contributes to bT~RM~ proliferation, the local brain microenvironment also modulates their density and influences their survival. bT~RM~ exhibit limited survival and proliferative capacity *in vitro* ([@bib64]); however, they do possess self-renewing capacity *in vivo* and display high proliferation during recall responses ([@bib59]). Similarly, we found increased proliferation of bT~RM~ upon Ag re-challenge, which suggests retention of their proliferative potential during recall responses. It has also been demonstrated that the density of skin T~RM~ influences local immune protection ([@bib13]).

We have previously reported that PD-1 is expressed at high levels on bT~RM~ ([@bib49]). Yet, despite this upregulation, in the current study bT~RM~ still displayed heightened proliferation and increased cytokine production in response to cognate Ag. This observation further supports the hypothesis that PD-1 is not simply a marker of exhaustion. These findings are in line with those of other studies wherein PD-1^+^CD8^+^ T~RM~ displayed transcriptional profiles with effector phenotypes, and showed clonal expansion ([@bib47]). PD-1 expression on activated cells is well known to shut down responses to prevent immunopathology ([@bib54]). However, in HIV-1 infection it appears that PD-1 expression on bT~RM~ may influence their functional properties in an inflamed brain microenvironment. Therefore, it will be of great interest to further define the roles of PD-1 on bT~RM~ in cART-treated and untreated patients.

T~RM~ are a unique type of memory T cell, specifically tailored to survive in non-lymphoid tissues. However, prolonged bT~RM~-driven recall responses in a microenvironment that normally lacks routine immune surveillance could be problematic. Persistent neuroimmune activation in response to viral reactivation may result in extensive damage to this largely non-regenerating tissue. Published reports show that a low copy number of HIV-1 provirus can still be intermittently detected in the CSF of patients receiving cART ([@bib57], [@bib68]), and persistent CNS inflammation is important to consider during HAND therapy ([@bib51]). In experimental models, despite low levels of virus, chronically HIV-infected NSG-hCD34^+^ mice show features of HAND (i.e., brain pathology including activation of microglia, upregulation of neuroinflammatory markers such as Mac1, an indicator of microgliosis, and iNOS), as well as neurodegeneration ([@bib5], [@bib51]). In our study, Ag-specific AI9 restimulation *in vivo* showed rapid upregulation of the microglial activation markers MHC-II and PD-L1 at both 2 and 5 days post-restimulation. Furthermore, real-time RT-PCR data from *ex vivo* restimulation experiments demonstrate that recall responses from bT~RM~ are capable of driving microglial cell activation, chemokine production, and production of iNOS. These data demonstrate that glial cells develop reactive phenotypes following the recall response of bT~RM~ to re-challenge with cognate Ag, but not in response to stimulation with non-specific T cell epitopes. Previous studies from our laboratory have identified glial cells as an important source of proinflammatory cytokines and chemokines ([@bib8], [@bib9], [@bib31]). Reports have shown that the potent T cell chemoattractants CXCL9 and CXCL10 are produced within inflamed brain and that their expression is enhanced by IFN-γ ([@bib30], [@bib41], [@bib45]). Similarly, in this study elevated levels of CXCL9 and CXC10 were observed, expression of which was significantly reduced following blockade of IFN-γ. Production of IFN-γ was found to be specific to the CD8^+^ T cells as demonstrated by our qPCR data. Following *ex vivo* AI9 restimulation, our data indicate that this cytokine is a driving force for glial cell activation. These findings have implications for neurodegenerative processes by releasing cytotoxic factors such as nitric oxide (NO), as well as several neurotoxic proinflammatory cytokines ([@bib7], [@bib39]).

Properly regulated neuroimmune responses strike a balance between pathogen clearance and an acceptable level of bystander tissue damage. In cART-treated patients with HAND, there is evidence of lingering, long-term astrocyte activation ([@bib63], [@bib66]). As is the case with microglia, astrocytes also respond to T cell- and microglial cell-produced immune mediators to acquire reactive phenotypes ([@bib28]). This cellular activation is routinely visualized by an upregulation of GFAP, a marker of astrogliosis ([@bib6]). Here, IHC staining of brain sections from prime-CNS boost mice subjected to recall stimulation further demonstrates the effect of bT~RM~ on glial cell reactivity. Co-localization of MHC-II and Iba-1, as well as GFAP and CXCL10, highlights recall-response-driven reactive phenotypes in both these glial cell types.

In summary, the results reported here demonstrate that our heterologous prime-CNS boost model induces a population of HIV-1-specific bT~RM~, which persist long term. As viral reactivation from CNS reservoirs appears likely even in cART-experienced patients, this model was used to demonstrate that antiviral recall responses from bT~RM~ can induce tissue-wide reactive gliosis through cytokine-induced activation of brain-resident glia. This cytokine-induced reactive gliosis may protect against viral spread throughout the brain, but it likely has cumulative neurotoxic consequences.

Limitations of the Study {#sec3.1}
------------------------

There is no ideal animal model that allows for the invasive study necessary to understand HIV reactivation from brain reservoirs and its association with HAND. It is also unlikely that *in vivo* restimulation with AI9 peptide exactly mimics transient viral protein production within human brain. However, use of this heterologous prime-boost model results in the murine brain being populated by resident memory CD8^+^ T cells specific for an immunodominant HIV Gag epitope. Subsequent *in vivo* recall neuroimmune responses can then be induced.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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